Anzeige
Mehr »
Dienstag, 23.12.2025 - Börsentäglich über 12.000 News
Breaking News: "Königs-Exosomen" senken Entzündungslevel um 90%…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
22.12.25 | 20:01
25,460 Euro
+0,39 % +0,100
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
25,10025,50022.12.
25,22025,47022.12.

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrTakeda to seek approval of plaque psoriasis pill on Phase III trial data3
FrTakeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis Trials15
DoTakeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug19
DoTakeda posts late-stage trial win for oral plaque psoriasis therapy4
DoTakeda says $4B TYK2 drug succeeds in large psoriasis studies7
DoTakeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success9
DoTakeda plans filings for Sotyktu rival on new psoriasis data3
DoTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::ZASOCITINIB LANDMARK PH3 PLAQUE PSO DATA SHOW PROMISE TO DELIVER CLEAR SKIN IN A ONCE-DAILY PILL13
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
DoTAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer3
DoTakeda's oral psoriasis drug meets all endpoints in phase 3 trials16
MiTakeda ist neuer Pharmapartner bei BaseLaunch7
16.12.Takeda Joins BaseLaunch Biotech Venture Incubator14
16.12.Takeda Canada: British Columbia Now Reimburses FRUZAQLA283TOKYO (dpa-AFX) - Takeda Canada announced that FRUZAQLA - fruquintinib capsules - will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer...
► Artikel lesen
08.12.ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap12
08.12.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer4
08.12.Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages13
08.12.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::PROTAGONIST AND TAKEDA PRESENT LONGER-TERM DATA AT ASH 2025 FOR RUSFERTIDE4
06.12.Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera605TOKYO (dpa-AFX) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera...
► Artikel lesen
05.12.Fierce Pharma Asia-FDA safety probe of Takeda drug; Otsuka kidney disease nod; ADC patent fight6
05.12.Takeda and Innovent fulfil close conditions for ADC and IO therapies5
Weiter >>
171 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2